

CERTIFICATE OF ANALYSIS - TECHNICAL DATA SHEET

Product name SP-B, Human, pAb

Catalog number HP9049-20UG

Lot number - Expiry date -

Volume 200 μl Amount 20 μg

Formulation 0.2 μm filtered in PBS+0.1%BSA+0.02%NaN3 Concentration 100 μg/ml

Host Species Rabbit IgG Conjugate None

Endotoxin N.A. Purification Protein A

Storage 4°C

Application notes

	IHC-F	IHC-P	IF	FC	FS	IA	IP	W
Reference #								
Yes	•	•				•		•
No								
N.D.			•	•	•		•	

N.D.= Not Determined; IHC = Immuno histochemistry; F = Frozen sections; P = Paraffin sections; IF = Immuno Fluorescence; FC = Flow Cytometry; FS = Functional Studies; IA = Immuno Assays; IP = Immuno Precipitation; W = Western blot

Dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50.

General Information

Description

The polyclonal antibody recognizes the human surfactant protein B (SP-B). There are four surfactant-specific proteins, designated surfactant protein A (SP-A), SP-B, SP-C and SP-D respectively. SP-A and SP-D are hydrophilic surfactant proteins and are members of the collectin family. SP-B and SP-C are hydrophobic surfactant proteins and may be the most appropriate indicators for the evolutionary origin of surfactant. SP-B is synthesized by the alveolar type II epithelial cells as a 40-42 kD precursor that is subsequently proteolytically processed to 7.8-8 kD. SP-B enhances the spreading and stability of surfactant phospholipids in the alveolus. SP-B is essential for air-breathing in mammals and is therefore largely conserved. SP-B can interact with both phospholipid head groups and fatty chains and is particularly active in enhancing surface active behaviour in endogenous and exogenous lung surfactants. Even low SP-B contents had measurable effects in increasing the adsorption, dynamic surface tension lowering, and/or film respreading of DPPC, mixed synthetic lipids, and column-purified lung surfactant phospholipids. Deficiency of SP-B and other surfactant components is associated with respiratory distress syndrome (RDS) in premature infants and adults with respiratory distress syndrome (ARDS). The polyclonal antibody is raised against human-based 60-amino acid synthetic SP-B polypeptide. The antibody recognizes proteins of 42, 25 and 18 kD under nonreducing conditions. The 18 kD form is reduced to 7.7-8 kD in the presence of beta-mercaptoethanol. The polyclonal antibody is cross reactive with mouse, bovine and pig SP-B.

Aliases SFTPB, previously SFTP3, Surfactant Protein B

Cross reactivity Mouse: Yes; Bovine: Yes; Pig: Yes.

References

- Whitsett, J et al; Immunologic identification of a pulmonary surfactant-assosiated protein of molecular weight = 6000 daltons. Pediatr Res 1986, 20: 744
- Weaver, T et al; Identification of surfactant proteolipid SP-B in human surfactant and fetal lung. J Appl Physiol 1988, 65: 982
- Gregory, T el al; Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome. J Clin Invest 1991, 88: 1976
- Clarck, J et al; Targeted disruption of the surfactant protein B gene disrupts surfactant homeostasis, causing respiratory failure in newborn mice. PNAS 1995, 92: 7794
- Nogee, L et al; Allelic heterogeneity in hereditary surfactant protein B (SP-B) deficiency. Am J Respir Crit Care Med 2000, 161: 973

Version: 08-2020

Storage&stability

Product should be stored at 4°C. Under recommended storage conditions, product is stable for at least one year.

Precautions

For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result from the use or derivation of this product.

We hereby certify that the above-stated information is correct and that this product has been successfully tested by the Quality Control Department. This product was released for sale according to the existing specifications. This document has been produced electronically and is valid without a signature.

Approved by Manager of QC Brenda Teunissen

Date 31/03/2021

Do you have any questions or comments regarding this product? Please contact us via support@hycultbiotech.com.

Version: 08-2020